首页> 外文OA文献 >P336 Association between the prior duration of remission and efficacy outcomes in patients with Ulcerative Colitis treated with tofacitinib 10 mg twice daily who were in stable remission and either dose-reduced to tofacitinib 5 mg twice daily or remained on 10 mg twice daily: 6-month data from the double-blind, randomised RIVETING study

【2h】

P336 Association between the prior duration of remission and efficacy outcomes in patients with Ulcerative Colitis treated with tofacitinib 10 mg twice daily who were in stable remission and either dose-reduced to tofacitinib 5 mg twice daily or remained on 10 mg twice daily: 6-month data from the double-blind, randomised RIVETING study

机译：P336在患有溃疡性结肠炎的患者的缓解和疗效结果之间的关联，溃疡性转子10毫克每天两次治疗，均为稳定的缓解，每天两次减少到Tofacitinib 5毫克，或每日两次留在10毫克：6个月来自双盲，随机铆接研究的数据

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
M C Dubinsky; G R D’Haens; W J Sandborn; S C Ng; J Panés; C Su; N Lawendy; I Lazariciu; S Gardiner; R Mundayat; N Kulisek; I Modesto; J Torres;
展开▼
作者单位

展开▼
年度 2021
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献

1. Comparison of efficacies of once-daily dose multimatrix mesalazine and multiple-dose mesalazine for the maintenance of remission in ulcerative colitis: a randomized, double-blind study [J] . Ogata Haruhiko, Ohori Akihiro, Nishino Haruo, Intestinal research. . 2017,第3期

机译：每日一次剂量多药美沙拉嗪和多剂量美沙拉嗪维持溃疡性结肠炎缓解的疗效比较：一项随机，双盲研究
2. Multiple esophageal ulcers due to tofacitinib 10 mg twice daily for ulcerative colitis [J] . Clinical journal of gastroenterology . 2020,第3期

机译：多种食管溃疡由于Tofacitinib 10 mg每天两次，用于溃疡性结肠炎
3. Tofacitinib 15 Milligrams Twice Daily for Patients With Moderate to Severe Ulcerative Colitis: Results From 8-Week Induction Studies OCTAVE Induction 1 & 2 [J] . Rubin David T., Motoya Satoshi, Schreiber Stefan, The American Journal of Gastroenterology . 2018,第Suppla2期

机译：汤克替尼每日两次为中度至重度溃疡性结肠炎的患者：8周诱导研究八度诱导1和2的结果
4. Comparison of efficacies of once-daily dose multimatrix mesalazine and multiple-dose mesalazine for the maintenance of remission in ulcerative colitis: a randomized double-blind study [O] . Haruhiko Ogata, Akihiro Ohori, Haruo Nishino, 2017

机译：每日一次剂量多药美沙拉嗪和多剂量美沙拉嗪维持溃疡性结肠炎缓解的疗效比较：一项随机双盲研究
5. P409 Non-invasive predictors of maintaining remission in patients with moderately to severely active Ulcerative Colitis treated with tofacitinib who dose-reduced from tofacitinib 10 mg twice daily to 5 mg twice daily: 6-month data from the double-blind, randomised RIVETING study [O] . G R D’Haens, M C Dubinsky, M Regueiro, 2021

机译：P409维持患者缓解患者的无侵袭性预测因子，以严重的患者对汤法替尼治疗的严重活性溃疡性结肠炎，他每天两次从TOFACITINIB 10 mg减少至5毫克：6个月的双盲，随机铆接研究数据

著录项

相似文献

相关主题

期刊订阅